Summarized by Masters of Longevity from Fight Aging!.
Initial human data show an inducible partial epigenetic reprogramming therapy delivered to the eye was safe through 56 days and produced early visual improvements in some patients.
Key Takeaways
- A single intravitreal AAV delivery of inducible OSK plus oral doxycycline was well tolerated through Day 56 in three participants.
- Two of three open-angle glaucoma participants showed Humphrey Visual Field improvements with ≥28% of points improving by more than 4 dB.
- No dose-limiting toxicities, serious adverse events, or adverse events of special interest were reported in the interim 56-day readout.
